Cytogen

Cytogen, founded in 2013, is a precision medicine company that owns a circulating tumor cell (CTC)-based liquid biopsy platform.

Based on proprietary technology that isolates living CTCs without damage, the company provides cancer diagnostic services and support for anticancer drug development, expanding a platform business model that extends beyond diagnostics into the entire drug development process.

It is discovering new CTC-based biomarkers across major cancer types including prostate, pancreatic, and breast cancer, with the data intended to support companion diagnostic strategies and investigational new drug application filings.

In 2024 the company acquired a 99.89% stake in Genomecare, a prenatal and postnatal genetic testing specialist, diversifying its business, and it also operates drug development support services for pharmaceutical companies alongside medical device distribution and health supplement sales.

Genomecare focuses on non-invasive prenatal testing and other genetic testing services, and has entered the public procurement market through contracts with the Public Procurement Service.

Overseas, Cytogen has established a US subsidiary (CLIA lab Expertox) and a Japan subsidiary in Tokyo to accelerate global market entry, strengthening its position through joint research on CTC platforms with Japan's National Cancer Center and partnerships with major Japanese biotech firms.

Domestically, a number of similar precision diagnostics and liquid biopsy technology companies exist, forming a competitive landscape. Structurally, the business rests on two pillars: the core CTC diagnostics and drug-development-support segment, and the newer Genomecare genetic testing segment.

Consolidated revenue in 2025 reached KRW 26.05 billion, up sharply from KRW 10.91 billion in 2024, and revenue scale has clearly expanded over the past two years compared to KRW 3.18 billion in 2023 and KRW 0.76 billion in 2022.

Operating loss narrowed from KRW 11.50 billion in 2022 and KRW 11.79 billion in 2023, to KRW 10.67 billion in 2024 and KRW 8.16 billion in 2025, while the operating margin improved from -1,511.3% in 2022 and -370.3% in 2023 to -97.8% in 2024 and -31.3% in 2025 as revenue scaled up.

Net loss attributable to owners also declined from KRW 18.77 billion in 2022 and KRW 15.77 billion in 2023, to KRW 17.12 billion in 2024 and KRW 12.34 billion in 2025.

On a quarterly basis, revenue was KRW 6.29 billion with an operating loss of KRW 1.93 billion in the second quarter of 2025, KRW 7.63 billion in revenue (the year's peak) with an operating loss of KRW 1.31 billion in the third quarter, and KRW 6.55 billion in revenue with an operating loss of KRW 2.56 billion in the fourth quarter.

However, the fourth-quarter 2025 net loss attributable to owners of KRW 5.46 billion was notably larger than the operating loss, suggesting additional non-operating factors affected results that period.

Entering 2026, first-quarter revenue was KRW 6.38 billion with an operating loss of KRW 1.47 billion and a net loss of KRW 1.27 billion, while second-quarter revenue reached KRW 6.83 billion with an operating loss of KRW 1.22 billion and a net loss of KRW 2.20 billion, showing revenue continuing a gradual uptrend while the operating loss narrowed year-on-year.

Over the trailing four quarters (third quarter of 2025 through second quarter of 2026), combined revenue was approximately KRW 27.3 billion, with a net loss attributable to owners of about KRW 10.5 billion.

Management attributes the improvement to the Genomecare acquisition, emerging overseas revenue, and cost-efficiency measures including reduced selling and administrative expenses.

Liquid biopsy is regarded as a next-generation precision medicine technology gaining attention in cancer diagnosis and monitoring markets, offering greater accuracy and convenience compared to tissue biopsy.

Unlike most liquid biopsy companies that rely on circulating tumor DNA derived from destroyed cancer cells, Cytogen differentiates itself by isolating circulating tumor cells (CTCs) from blood in a living state.

Its Japan subsidiary is strengthening its local market position through joint research on CTC platforms with Japan's National Cancer Center, part of an integrated platform strategy that extends from diagnostics into drug development support.

The company is discovering new CTC-based biomarkers across ten major cancer types including prostate, pancreatic, and breast cancer, and plans to link this to companion diagnostic strategies for patient selection and drug response prediction in future clinical stages.

Domestically, similar precision diagnostics and genetic testing technology companies exist, creating ongoing competition, and Genomecare's non-invasive prenatal testing business also operates within a competitive domestic genetic testing market.

The company's revenue scale remains relatively small in absolute terms, positioning it in a segment of the industry where its standing could be reassessed depending on whether rapid top-line growth is accompanied by continued profitability improvement.

The company has stated it is scaling up an integrated CTC-based drug development solution business, and plans to expand similar partnership models with domestic and overseas pharmaceutical companies going forward to sustain earnings growth.

Genomecare has been accelerating market share expansion by entering the public procurement market through contracts with South Korea's Public Procurement Service, a channel diversification that could contribute to future revenue stability.

In Japan, the company is pursuing expanded CTC analysis services based on cooperation with the National Cancer Center and local biotech firms, while in the United States it is building distribution networks through its CLIA lab, leaving the materialization of overseas revenue as a key point to watch in future earnings.

When reporting first-quarter 2026 results, the company noted that successful M&A synergies and emerging overseas revenue had laid the groundwork for an earnings turnaround.

However, this growth strategy has been accompanied by continuous external fundraising, meaning future convertible bond conversions and new financing plans could affect the pace of business expansion.

On the governance side, since the shift to a sole-CEO structure, decision-making centered on the newer Genomecare business appears to have strengthened, which is a variable that could affect the execution speed of the diversification strategy.